Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Operating Expenses (2021 - 2025)

Kiniksa Pharmaceuticals International's Other Operating Expenses history spans 5 years, with the latest figure at $91.0 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 37.66% year-over-year to $91.0 million; the TTM value through Dec 2025 reached $312.5 million, up 65.17%, while the annual FY2025 figure was $307.2 million, 62.36% up from the prior year.
  • Other Operating Expenses reached $91.0 million in Q4 2025 per KNSA's latest filing, up from $83.6 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $91.0 million in Q4 2025 to a low of $2.5 million in Q2 2021.
  • Average Other Operating Expenses over 5 years is $34.1 million, with a median of $26.4 million recorded in 2023.
  • Peak YoY movement for Other Operating Expenses: surged 317.78% in 2022, then rose 22.86% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $4.7 million in 2021, then skyrocketed by 202.68% to $14.2 million in 2022, then skyrocketed by 86.36% to $26.5 million in 2023, then skyrocketed by 149.16% to $66.1 million in 2024, then surged by 37.66% to $91.0 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Other Operating Expenses are $91.0 million (Q4 2025), $83.6 million (Q3 2025), and $71.0 million (Q2 2025).